Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Previous studies have demonstrated low rates of seroconversion to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients with chronic lymphocytic leukemia (CLL). In this national collaboration of 11 cancer centers in the United States, we aimed to furt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ujjani, Chaitra, Gooley, Ted A., Spurgeon, Stephen E., Stephens, Deborah M., Lai, Catherine, Broome, Catherine M., O’Brien, Susan, Zhu, Haiying, Laing, Kerry J., Winter, Allison M., Pongas, Georgios, Greninger, Alexander L, Koelle, David M., Siddiqi, Tanya, Davids, Matthew S., Rogers, Kerry A., Danilov, Alexey V., Sperling, Amy, Tu, Brian, Sorensen, Tyler, Launchbury, Kelsey, Burrow, Carlissa J., Quezada, Genesis, Hill, Joshua A., Shadman, Mazyar, Thompson, Philip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906469/
https://www.ncbi.nlm.nih.gov/pubmed/36516082
http://dx.doi.org/10.1182/bloodadvances.2022009164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906469/
https://www.ncbi.nlm.nih.gov/pubmed/36516082
http://dx.doi.org/10.1182/bloodadvances.2022009164

Ejemplares similares